Abstract

Aim To evaluate the effects of luteolin against amyloid beta-peptide 25–35 (Aβ 25–35) on rat cerebral microvascular endothelial cells (CMECs). Methods CMECs were isolated from Wistar rats at 3-week-old, and randomly divided into 5 groups including control group, Aβ 25–35 group, 0.1, 1.0, and 10.0 μmol·L −1 luteolin groups. Cell viability was determined with MTS assay. Intracelluar ROS level and SOD activity were monitored by DCFH-DA and SOD inhibition assay, respectively. Transendothelial electrical resistance was measured using an EVOM resistance meter. γ-Glutamyl transpeptidase and alkaline phosphatase activities were detected using activity assay kits. Levels of TXA 2 and PGI 2 in culture medium were measured as their stable metabolites, TXB 2 and 6-keto-PGF 1α, by ELISA. Results Luteolin attenuated Aβ 25–35-induced toxicity at 0.1, 1.0, and 10 μmol·L −1, inhibited intracellular ROS generation, and increased SOD activity at 1.0 and 10 μmol·L −1. Luteolin was also found to preserve CMECs barrier function, involving the alleviation of TEER reduction, the increase of characteristic enzymatic activity, and regulation of TXA 2 and PGI 2 secretion. Conclusion Luteolin had the ability to protect rat CMECs against Aβ 25–35-induced toxicity.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call